WHO evaluates vaccines, treatments for Ebola outbreak

On May 17, 2026, the World Health Organization (WHO) declared the Ebola outbreak in the Democratic Republic of Congo (DRC) and Uganda a Public Health Emergen...

What Happened

On May 17, 2026, the World Health Organization (WHO) declared the Ebola outbreak in the Democratic Republic of Congo (DRC) and Uganda a Public Health Emergency of International Concern (PHEIC) — the highest level of global health alarm under the International Health Regulations (IHR), 2005.
The outbreak is caused by the Bundibugyo strain of Ebola virus, for which there is currently no approved vaccine or therapeutic treatment, unlike the more common Zaire strain for which the Ervebo vaccine exists.
As of May 19, 2026, the outbreak had recorded over 500 suspected cases with at least 131 confirmed deaths — making it the third documented Bundibugyo outbreak on record and by far the largest.
A major diagnostic challenge compounded the response: rapid field tests used for screening are calibrated for the Zaire species and initially returned negative results for Bundibugyo cases; genomic sequencing at a reference laboratory in Kinshasa was required for correct identification.
WHO is actively evaluating experimental vaccines and therapeutics in early development stages, though none are near regulatory approval or ready for emergency deployment.
The outbreak has triggered WHO's R&D Blueprint activation, a framework established after the 2014–2016 West Africa Ebola epidemic to accelerate development of tools against priority pathogens.

Static Topic Bridges

Public Health Emergency of International Concern (PHEIC)

A Public Health Emergency of International Concern is the highest formal alert the WHO can issue under the International Health Regulations (IHR), 2005. It signifies an extraordinary public health event that constitutes a risk to other states through international spread and potentially requires a coordinated international response.

PHEIC declarations are made by the WHO Director-General on the recommendation of an Emergency Committee convened under Article 12 of the IHR, 2005.
A PHEIC triggers obligations on WHO member states including enhanced surveillance, reporting, and border health measures.
Previous PHEICs include: Swine Flu (H1N1) in 2009, Polio in 2014, West Africa Ebola in 2014, Zika in 2016, Kivu Ebola in 2019, COVID-19 in 2020, Monkeypox/Mpox in 2022, and Mpox again in 2024.
India has obligations under the IHR 2005 as a State Party to strengthen its core public health capacities and report potential PHEICs to WHO.

Connection to this news: The PHEIC declaration for the Bundibugyo outbreak activates international solidarity mechanisms for vaccine development, surge financing (through the Pandemic Fund and CEPI), and coordinated border health surveillance — all critical given the absence of approved countermeasures.

Ebola Virus Disease: Biology, Strains, and Transmission

Ebola Virus Disease (EVD) is a severe hemorrhagic fever caused by viruses in the genus Ebolavirus, family Filoviridae. First identified in 1976 near the Ebola River in what is now the DRC, it has caused over 30 outbreaks across sub-Saharan Africa over the subsequent five decades.

There are six known Ebolavirus species: Zaire ebolavirus (most deadly, case fatality rate up to 90%), Sudan ebolavirus, Bundibugyo ebolavirus, Reston ebolavirus (non-pathogenic in humans), Tai Forest ebolavirus, and Bombali ebolavirus.
Transmission occurs through direct contact with bodily fluids (blood, vomit, faeces) of infected persons or deceased individuals; it is not airborne.
The natural reservoir is believed to be fruit bats; the virus is zoonotic, spilling over to humans through contact with infected animals or bushmeat.
Case fatality rates range from 22% to 88% depending on the strain, quality of healthcare response, and timing of supportive care.
Bundibugyo ebolavirus was first identified in 2007 in an outbreak in Bundibugyo District, western Uganda (116 cases, 39 deaths); it re-emerged in DRC in 2012 (36 cases, 13 deaths). The 2026 outbreak is the third known Bundibugyo event.

Connection to this news: The Bundibugyo strain's status as a relatively rare and under-researched variant explains why no vaccine exists — research investment has historically been concentrated on the Zaire strain responsible for most large outbreaks.

WHO R&D Blueprint and Emergency Vaccine Evaluation

The WHO R&D Blueprint is a global strategy launched in 2016 to enable rapid development and equitable availability of vaccines, diagnostics, and therapeutics during public health emergencies. It maintains a priority pathogen list — diseases for which countermeasures are inadequate and outbreaks could cause a public health emergency.

Ebola (all strains) appears on the WHO priority pathogen list; the R&D Blueprint was specifically created in response to the gaps exposed by the 2014–2016 West Africa Ebola epidemic.
CEPI (Coalition for Epidemic Preparedness Innovations), established in 2017 at Davos with backing from multiple governments and the Bill & Melinda Gates Foundation, funds early-stage vaccine development for WHO priority pathogens including Bundibugyo ebolavirus.
The Ervebo vaccine (rVSV-ZEBOV) is approved for Zaire ebolavirus; animal studies show it provides poor cross-protection against Bundibugyo, necessitating strain-specific countermeasure development.
Emergency Use Listing (EUL) by WHO is a pathway by which unregistered vaccines or therapeutics can be used in public health emergencies even before full licensure, subject to ongoing efficacy and safety data collection.

Connection to this news: WHO's evaluation of Bundibugyo-specific experimental vaccines is occurring under the R&D Blueprint framework, but the absence of any candidate in human trials means the outbreak is being managed with supportive care alone — highlighting the risk gap in global health preparedness for uncommon pathogen variants.

International Health Regulations (IHR) 2005 and Global Health Governance

The International Health Regulations (IHR), 2005, are a legally binding international instrument — binding on 196 countries including all WHO Member States — that define rights and obligations in handling public health events with the potential for cross-border spread.

The IHR require member states to develop core capacities for disease surveillance, laboratory testing, response, and points-of-entry health measures.
The 2022–2024 IHR amendment process, concluded at the World Health Assembly in May 2024, strengthened provisions on equity, surveillance, and pandemic preparedness financing while preserving national sovereignty over health emergency responses.
India is a signatory to the IHR 2005 and has designated National IHR Focal Points for notification and coordination.
The IHR framework was tested and found inadequate during COVID-19; reforms aim to improve early warning systems, information sharing, and technology transfer to lower-income countries.

Connection to this news: The PHEIC declaration for the Bundibugyo Ebola outbreak activates IHR provisions requiring member states, including India, to assess import risk, strengthen port health surveillance, and report any suspected imported cases to WHO within 24 hours.

Ebola and India's Preparedness Obligations

India has not recorded a domestically transmitted Ebola case, but the risk of an imported case exists given direct air connectivity with African cities. The National Centre for Disease Control (NCDC) and the Indian Council of Medical Research (ICMR) are the nodal agencies for EVD surveillance and response.

India established special isolation facilities and border health surveillance protocols following each major Ebola PHEIC, including in 2014 and 2019.
The National Action Plan for Health Security (NAPHS), developed under the Global Health Security Agenda (GHSA), outlines India's IHR core capacity commitments.
BSL-4 (Biosafety Level 4) laboratory capability — required for working with live Ebola virus — exists at ICMR-National Institute of Virology (NIV) in Pune.
India participates in WHO's Global Outbreak Alert and Response Network (GOARN), which deploys expert teams for outbreak investigation and response.

Connection to this news: While India's immediate exposure risk from the current DRC/Uganda outbreak is low, the PHEIC status requires India to activate its IHR-mandated surveillance protocols at international airports and ports of entry.

Key Facts & Data

PHEIC declared: May 17, 2026, by WHO Director-General.
Outbreak scope as of May 19, 2026: over 500 suspected cases, at least 131 deaths.
Bundibugyo outbreaks on record: three — 2007 (Uganda), 2012 (DRC), 2026 (DRC and Uganda).
First Ebola outbreak: 1976, DRC; over 30 outbreaks recorded since.
Total Ebola deaths in Africa since 1976: over 15,000 (including the 2014–2016 West Africa epidemic).
Largest Ebola outbreak: 2014–2016 West Africa (Guinea, Liberia, Sierra Leone); over 28,600 cases.
Approved vaccine against Zaire ebolavirus: Ervebo (rVSV-ZEBOV); not effective against Bundibugyo strain.
Bundibugyo case fatality rate (2007 outbreak): approximately 34% (39 deaths in 116 cases).
CEPI established: 2017 (Davos World Economic Forum), to fund epidemic preparedness vaccines.
India's BSL-4 laboratory: ICMR-National Institute of Virology (NIV), Pune.